Skip to main content
Publications
Danysh HE , Gilsenan A , Kaye JA, Garcia de Albeniz Martinez X , Schmid R, Bartsch J , Calingaert B , Rahman S, Layton JB , Gutierrez L . Validation of algorithms to identify breast cancer and bladder cancer among patients with type 2 diabetes mellitus in United States medicare administrative claims . Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Johannes CB , Ziemiecki R , Pladevall-Vila M , Kosvesdy CP, Ebert N, Thomsen RWW, Christiansen CF, Baak B, Cabaninas CR, Kashihara N, Yano Y, Kanegae H, Coleman CI, Okami S, Li u F, Layton JB , Vizcaya D, Oberprieler NG. Use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease: a multicountry report from the FOUNTAIN platform . Poster presented at the 2024 ISPE Annual Meeting; August 26, 2024. Berlin, Germany.
Pajouheshnia R , Gini R, Gutierrez L , Swertz MA, Hyde E, Sturkenboom M, Arana A , Franzoni C , Ehrenstein V, Roberto G, Gil M, Macia MA, Schafer W, Haug U, Thurin NH, Lassalle R, Droz-Perroteau C, Zaccagnino S, Busto MP, Middelkoop B, Gembert K, Sanchez-Saez F, Rodriguez-Bernal C, Sanfelix-Gimeno G, Hurtado I, Barreiro-de Acosta M, Poblador-Plou B, Carmona-Pirez J, Gimeno-Miguel A, Prados-Torres A, Schultze A, Jansen E, Herings R, Kuiper J, Locatelli I, Jazbar J, Zerovnik S, Kos M, Smit S, Lind S, Metspalu A, Simou S, Hedenmalm K, Cochino A, Alcini P, Kurz X, Perez-Gutthann S . Metadata for data dIscoverability aNd study rEplicability in obseRVAtional studies (MINERVA): development and pilot of a metadata list and catalogue in Europe . Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5871. doi: 10.1002/pds.5871
Gini R, Pajouheshnia R , Gardarsdottir H, Bennett D, Li L, Gulea C, Wientzek-Fleischmann A, Bazelier MT, Burcu M, Dodd C, Duran CE, Kaplan S, Lanes S, Marinier K, Roberto G, Soman K, Zhou X, Platt R, Setoguchi S, Hall GC. Describing diversity of real world data sources in pharmacoepidemiologic studies: the DIVERSE scoping review . Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5787. doi: 10.1002/pds.5787
Rebordosa C , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia-Esteban R , Plana E , Tormos A , Farsani SF, Perez-Gutthann S , Pladevall-Vila M . Liver, renal, genitourinary, and diabetic ketoacidosis risks among new users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes: post-authorisation safety study based on multinational cohorts . Diabetes Obes Metab. 2024 Apr;26(4):1291-304. doi: 10.1111/dom.15429
Anthony MS , Aroda VR, Parlett LE, Djebarri L, Berreghis S, Calingaert B , Beachler DC, Crowe CL, Johannes CB , Juhaeri J, Lanes S, Pan C, Rothman KJ , Saltus CW , Walsh KE. Risk of anaphylaxis among new users of glp-1 receptor agonists: a cohort study . Diabetes Care. 2024 Apr 1;47(4):712-9. doi: 10.2337/dc23-1911
Keens T, Hoffman V , Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis . Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
Desai RJ, Wang SV, Sreedhara SK, Zabotka L, Khosrow-Khavar F, Nelson JC, Shi X, Toh S, Wyss R, Patorno E, Dutcher S, Li J, Lee H, Ball R, Dal Pan G, Segal JB, Suissa S, Rothman KJ , Greenland S, Hernan MA, Heagerty PJ, Schneeweiss S. Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center . BMJ. 2024 Feb 12;384:e076460. doi: 10.1136/bmj-2023-076460
Oberprieler NG, Kovesdy CP, Layton JB , Gay A, Farjat AE, Liu F, Johannes CB , Pladevall-Vila M , Vizcaya D. Early use and effectiveness of finerenone in US patients with CKD and type 2 diabetes: a FOUNTAIN platform analysis . Poster presented at the Kidney Week 2023; November 2, 2023. Philadelphia, PA.
Hageman SH, Petitjean C, Pennells L, Kaptoge S, Pajouheshnia R , Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, Klungel OH, Souverein PC, van der Schouw YT, Verschuren WM, Lehmann N, Erbel R, Jockel KH, Di Angelantonio E, Visseren FL, Dorresteijn JA. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2 . Eur J Prev Cardiol. 2023 Oct 26;30(15):1705-14. doi: 10.1093/eurjpc/zwad187
Tormos A , Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D , Garcia Esteban R , Plana E , Farsani SF, Perez-Gutthann S , Pladevall-Vila M , Rebordosa C . Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D) . Poster presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):585. doi: 10.1002/pds.5687
Mayer SE, Fuller CC, Haynes K, Alam S, Brown JS, Daniels K, Hawrusik R, Horgan C, Jamal-allial A, Johannes CB , Kawai AT , Layton JB , Mai X, Marshall J, McMahill-Walraven CN, Reynolds JS, Seals R, Selvan M, Stemkowski S, Wang FT, Yost E, Gilsenan A , Platt R. Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 vaccines in four large US national insurers . Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):186. doi: 10.1002/pds.5687
Layton JB , Peetluk LS, Wong H, Jiao Y, Ogilvie RP, Miller M, Glazier-Essalmi A, Parambi RJ, Song J, Garcia de Albeniz Martinez X , Lloyd PC, Lo A, Kawai A , Weatherby L, Bell EJ, Yang G, Amend KL, Gruber JF, Clarke TC, Forshee RA, Anderson SA, Wernecke M, Matuska K, Chillarige Y, Anthony M , Seeger JD, Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States . Presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):608. doi: 10.1002/pds.5687
Thomsen RW, Andersen IT, Kristensen FP, Munch PV, Pladevall-Vila M , Johannes C , Saigi-Morgui N , Ziemiecki R , Layton J , Vizcaya D, Gay A, Farjat A, Liu F, Oberprieler N, Christiansen CF. Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and type 2 diabetes in Denmark: a nationwide population-based study part of the FOUNTAIN platform . Presented at the 59th Annual Meeting European Association for the Study of Diabetes (EASD) 2023; October 4, 2023. Hamburg, Germany.
Warkentin S, de Bont J, Abellan A , Pistillo A, Saucy A, Cirach M, Nieuwenhuijsen M, Khalid S, Basagana X, Duarte-Salles T, Vrijheid M. Changes in air pollution exposure after residential relocation and body mass index in children and adolescents: a natural experiment study . Environ Pollut. 2023 Oct 1;334:122217. doi: 10.1016/j.envpol.2023.122217
Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Douglas SRG, Rizzo RRN, Devonshire JJ, Williams SA, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X , Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne JAC, Sharp MK, Stuart EA, Hernan MA, Lee H, McAuley JH. Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review . JAMA Netw Open. 2023 Sep 5;6(9):e2336023. doi: 10.1001/jamanetworkopen.2023.36023